Cosmo N.V.

0RGI.L

Medical - Pharmaceuticals · Healthcare

Price

57.77 GBp

-0.59 (-1.02%)

Market Cap

£953.5M

Exchange

London Stock Exchange

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Dividends

Mixed

Track this stock — start free trial

Share count falling — buybacks

−5.5% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 16.9M (2021) → 16.0M (2025)

Winston Score History

The full picture

Cosmo Pharmaceuticals is a specialty drug company that focuses on medicines for the digestive system, particularly the colon and intestines. Its best-known product is Methylene Blue MMX, a dye used during colonoscopies to help doctors spot abnormal tissue more easily. The company also develops drug-device combinations and has licensed several products to larger pharmaceutical partners.

Cosmo makes money through a mix of product sales, royalties, and licensing deals with bigger drugmakers who sell Cosmo's products in various markets. It operates primarily in Europe and North America, and its main edge comes from patented drug-delivery technology that controls how and where a medicine is released in the gut. The company is currently unprofitable at the operating level, and its growth depends heavily on whether its pipeline products gain regulatory approval and whether licensing partners successfully commercialize the drugs they have licensed from Cosmo.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-3.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-115.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€32M/ year

↓ Declining (-19% vs prior year)

30.8% of revenue

1.7x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

47.7%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~6 years

€217M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

€217M cash & investments at current burn rate

Revenue declining

Cosmo N.V.'s revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

44.5%

Healthy — 44.5% gross margin

Profit after running costs

Operating Margin

-18.8%

Losing money on operations — -18.8%

Return on the money invested

ROCE

-2.4%

Weak — -2.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-43.7%

Shrinking sales (-43.7% YoY)

Profit growth

EPS YoY

-111.4%

Earnings shrinking (-111.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-23.2%

Burning cash (-23.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

3.34%

Moderate income — 3.34% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial